Categories AlphaGraphs, Earnings, Technology

VZ Earnings: Highlights of Verizon’s Q2 2022 financial results

Telecom giant Verizon Communications Inc. (NYSE: VZ)  on Friday reported lower profit and flat revenues for the second quarter of 2022. The top-line slightly beat the estimates, while earnings missed by a cent.

Verizon Q2 2022 earnings infographic

Second-quarter adjusted earnings declined to $1.31 per share from $1.39 per share in the comparable period of last year. Unadjusted profit dropped to $5.32 billion or $1.24 per share from $5.95 billion or $1.40 per share last year. Analysts were looking for a slightly bigger bottom line number.

Meanwhile, total operating revenues remained broadly unchanged at $33.79 billion, which was slightly above the consensus forecast.

Check this space to read management/analysts’ comments on Verizon’s Q2 2022 report

“As the market leader, in a very competitive industry, we are determined to improve our operational and financial performance for the second half of the year. With our network-as-a-service foundation, our new consumer mobility plans, and recent pricing actions, we are being deliberate in our decisions to improve our profitable growth opportunities today and into the future,” said Verizon’s CEO Hans Vestberg.

Prior Performance

  • Verizon Q1 2022 Earnings Infographic
  • Verizon Communications Q1 2021 earnings

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results

DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line

Macy’s (M): A few points to consider if you have an eye on this retailer

Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit

Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine

Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent

Add Comment
Viewing Highlight